Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	654.77B
Revenue (ttm)	1.29T
Net Income (ttm)	55.08B
Shares Out	6.44M
EPS (ttm)	8,555.12
PE Ratio	11.89
Forward PE	8.05
Dividend	1,844.66 (1.87%)
Ex-Dividend Date	Mar 13, 2025

Volume	5,894
Average Volume	17,401
Open	99,300
Previous Close	98,400
Day's Range	98,100 - 99,300
52-Week Range	90,583 - 124,757
Beta	0.12
RSI	61.48
Earnings Date	May 2, 2025

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,530
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2023, Dong-A Socio Holdings's revenue was 1.13 trillion, an increase of 11.54% compared to the previous year's 1.01 trillion. Earnings were 57.99 billion, an increase of 419.96%.